nach oben

Erschienen in:

01.07.2015 | Research Article

Effectiveness of surgery in liver metastasis from colorectal cancer: experience and results of a continuous improvement process

verfasst von: F. Navarro-Freire, P. Navarro-Sánchez, N. García-Agua, B. Pérez-Cabrera, A. Palomeque-Jiménez, J. A. Jiménez-Rios, P. A. García-López, A. J. García-Ruiz

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to estimate the effectiveness of surgery in liver metastasis from colorectal cancer.

Methods

We conducted a prospective and observational study of patients with colorectal liver metastasis operated on at the San Cecilio University Hospital of Granada from March 2003 until June 2013. The primary variables of the result were survival and morbidity before 30 days of the post-operative period. We also measured preoperative and surgical variables.

Results

A total of 147 patients with liver metastasis of colorectal origin underwent surgical removal during the period of study, 38 of whom had repeat surgery. 34 had a second resection, 3 had a third one and one only patient had a fourth one, for a total of 185 registered operations. The global 5-year survival rate was 38 and 17 % after 10 years. There were 115 patients who had neither radiofrequency nor exploratory laparotomy, 38 % of them survived over 60 months. The average disease-free time was 23.6 months ± 47.3, with significant differences observed between types of procedures. Patients that were operated on just once (n = 25) had a five-year actuarial survival rate of 35 %, a morbidity rate of 24 % and a mortality rate of 0.6 % (1 patient only). The average hospital stay was 13.8 days and the disease-free time was 15.8 months.

Conclusion

The results obtained in our surgical unit in terms of morbidity, mortality and five-year actuarial survival rates are comparable to those of other units at large institutions, which are currently considered the standards of quality.

World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 7 July 2014.

Spanish Statistical Office. Hospital Morbidity Survey. Available at: http://www.ine.es/jaxi/menu.do?type=pcaxis&path=%2Ft15%2Fp414&file=inebase&L=1. Accessed 7 July 2014.

World Health Organization. World health statistics 2008. Available at: http://www.who.int/gho/publications/world_health_statistics/EN_WHS08_Full.pdf. Accessed 7 July 2014.

Nordlinger B, Van CE, Gruenberger T, Glimelius B, Poston G, Rougier P, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20(6):985–92.PubMedCrossRef

Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.PubMedCentralPubMedCrossRef

Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93(4):465–74.PubMedCrossRef

Mayo SC, Heckman JE, Shore AD, Nathan H, Parikh AA, Bridges JF, et al. Shifting trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis. Surgery. 2011;150(2):204–16.PubMedCentralPubMedCrossRef

Andres A, Toso C, Adam R, Barroso E, Hubert C, Capussotti L, et al. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a livermetsurvey-based study. Ann Surg. 2012;256(5):772–8.PubMedCrossRef

Cardona K, Mastrodomenico P, D’Amico F, Shia J, Gonen M, Weiser MR, et al. Detailed pathologic characteristics of the primary colorectal tumor independently predict outcome after hepatectomy for metastases. Ann Surg Oncol. 2013;20(1):148–54.PubMedCrossRef

10.

Aloia TA, Adam R, Azoulay D, Bismuth H, Castaing D. Outcome following hepatic resection of metastatic renal tumors: the paul brousse hospital experience. HPB (Oxford). 2006;8(2):100–5.PubMedCentralCrossRef

11.

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–83.PubMedCentralPubMedCrossRef

12.

Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-Year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80.PubMedCrossRef

13.

House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival After hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–5.PubMedCrossRef

14.

Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.PubMedCentralPubMed

15.

Weiss MJ, D’Angelica MI. Patient selection for hepatic resection for metastatic colorectal cancer. J Gastrointest Oncol. 2012;3(1):3–10.PubMedCentralPubMed

16.

Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15(2):91–103.PubMedCentralCrossRef

17.

Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13(1):51–64.PubMedCrossRef

18.

Adam R, Hoti E, Folprecht G, Benson AB. Accomplishments in 2008 in the Management of Curable Metastatic Colorectal Cancer. Gastrointest Cancer Res. 2009;3(5 Supplement 2):S15–22 .PubMedCentralPubMed

19.

Adam R, Gramont De, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al. the oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17(10):1225–39.PubMedCentralPubMedCrossRef

20.

Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231(4):480–6.PubMedCentralPubMedCrossRef

21.

Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg. 2000;232(6):777–85.PubMedCentralPubMedCrossRef

22.

Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57.PubMedCentralPubMed

23.

Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist. 2007;12(7):825–39.PubMedCrossRef

24.

Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg. 2009;249(1):20–5.PubMedCrossRef

25.

De Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440–8.PubMed

26.

D’Angelica M, Kornprat P, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, et al. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol. 2011;18(4):1096–103.PubMedCrossRef

27.

Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12(5):351–5.PubMedCrossRef

28.

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18.PubMedCentralPubMedCrossRef

29.

Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The clavien-dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.PubMedCrossRef

30.

Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80.PubMedCrossRef

31.

Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982–99.PubMedCentralPubMedCrossRef

32.

Chowdhury MM, Dagash H, Pierro A. A systematic review of the impact of volume of surgery and specialization on patient outcome. Br J Surg. 2007;94(2):145–61.PubMedCrossRef

33.

Jones RP, Stattner S, Sutton P, Dunne DF, McWhirter D, Fenwick SW, et al. Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. Surg Oncol. 2014;23(2):53–60.PubMedCrossRef

34.

Jones RP, Jackson R, Dunne DF, Malik HZ, Fenwick SW, Poston GJ, et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg. 2012;99(4):477–86.PubMedCrossRef

35.

López R, Montalvá E, Moya A, Redondo C, San Juan F, Pareja E, et al. Reflections on 250 interventions for colorectal carcinoma metastases to the liver. Cir Esp. 2007;81(5):269–75.CrossRef

36.

Figueras J, Torras J, Valls C, Ramos E, Lama C, Busquets J. Resección de metástasis hepáticas de carcinoma colorrectal. índice De resecabilidad y supervivencia a largo Plazo. Cir Esp. 2001;70:27–33.CrossRef

37.

DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH, Fong Y. anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg. 2000;4(2):178–84.PubMedCrossRef

38.

Hemming AW, Scudamore CH, Davidson A, Erb SR. Evaluation of 50 consecutive segmental hepatic resections. Am J Surg. 1993;165(5):621–4.PubMedCrossRef

39.

Shirabe K, Takenaka K, Gion T, Fujiwara Y, Shimada M, Yanaga K, et al. Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin. Br J Surg. 1997;84(8):1077–80.PubMedCrossRef

40.

Hillingso JG, Wille-Jorgensen P. Staged or simultaneous resection of synchronous liver metastases from colorectal cancer—a systematic review. Colorectal Dis. 2009;11(1):3–10.PubMedCrossRef

41.

Santibañes De, Fernandez D, Vaccaro C, Quintana GO, Bonadeo F, Pekolj J, et al. Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases. World J Surg. 2010;34(9):2133–40.PubMedCrossRef

42.

Lykoudis PM, O’Reilly D, Nastos K, Fusai G. Systematic review of surgical management of synchronous colorectal liver metastases. Br J Surg. 2014;101(6):605–12.PubMedCrossRef

43.

Benoist S, Nordlinger B. Radiofrequency Ablation in Liver Tumours. Ann Oncol. 2004;15(Suppl 4):iv313–iv317.

44.

Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA. Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg. 2006;10(2):240–8.PubMedCrossRef

45.

Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol. 2005;12(11):900–9.PubMedCrossRef

46.

Chua TC, Saxena A, Liauw W, Chu F, Morris DL. Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases—a systematic review. Eur J Cancer. 2012;48(12):1757–65.PubMedCrossRef

47.

Bismuth H, Adam R, Navarro F, Castaing D, Engerran L, Abascal A. Re-resection for colorectal liver metastasis. Surg Oncol Clin N Am. 1996;5(2):353–64.PubMed

48.

Adam R, Bismuth H, Castaing D, Waechter F, Navarro F, Abascal A, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg. 1997;225(1):51–60.PubMedCentralPubMedCrossRef

49.

Adam R, Levi F, Navarro F. Combined treatment of iresectable liver metastases of colorectal cancer by chemotherapy and subsequent hepatic resection. Br J Surg 1992;79(suppl).

50.

Adair RA, Young AL, Cockbain AJ, Malde D, Prasad KR, Lodge JP, et al. Repeat hepatic resection for colorectal liver metastases. Br J Surg. 2012;99(9):1278–83.PubMedCrossRef

51.

Thelen A, Jonas S, Benckert C, Schumacher G, Lopez-Hanninen E, Rudolph B, et al. Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol. 2007;33(3):324–8.PubMedCrossRef

52.

Nishio H, Hamady ZZ, Malik HZ, Fenwick S, Rajendra PK, Toogood GJ, et al. Outcome following repeat liver resection for colorectal liver metastases. Eur J Surg Oncol. 2007;33(6):729–34.PubMedCrossRef

53.

Luo LX, Yu ZY, Huang JW, Wu H. Selecting patients for a second hepatectomy for colorectal metastases: an systemic review and meta-analysis. Eur J Surg Oncol. 2014.

54.

Langenhoff BS, Krabbe PF, Ruers TJ. Efficacy of follow-up after surgical treatment of colorectal liver metastases. Eur J Surg Oncol. 2009;35(2):180–6.PubMedCrossRef

Titel: Effectiveness of surgery in liver metastasis from colorectal cancer: experience and results of a continuous improvement process
verfasst von: F. Navarro-Freire
P. Navarro-Sánchez
N. García-Agua
B. Pérez-Cabrera
A. Palomeque-Jiménez
J. A. Jiménez-Rios
P. A. García-López
A. J. García-Ruiz
Publikationsdatum: 01.07.2015
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 7/2015
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1277-z

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Effectiveness of surgery in liver metastasis from colorectal cancer: experience and results of a continuous improvement process